| BHOF in the News, Osteoporosis in the News

In response to a recent NPR article detailing the positive results of a common osteoporosis drug, Elizabeth Thompson, NOF, CEO, said:  “When the experts in the field say that this study is “extremely important”, “highly effective”, and “a breakthrough”, we are making progress! Reducing suffering and maintaining life quality is important for our senior population—key areas of focus for our work at NOF.  As we launch our National Bone Health Policy Institute, these foundational studies that provide the data to show that treating patients early can make a difference in quality of life and savings to Medicare, remain important themes.”

The article details a large study, published Monday in the New England Journal of Medicine, that produced strong evidence showing the drug zoledronate, commonly used to treat the bone-thinning disease osteoporosis, could safely prevent fractures in elderly women who have bones that aren’t as weak.

Read the full article and more about this important work here.